PMID- 8972740
OWN - NLM
STAT- MEDLINE
DCOM- 19970116
LR  - 20190818
IS  - 0300-9475 (Print)
IS  - 0300-9475 (Linking)
VI  - 44
IP  - 6
DP  - 1996 Dec
TI  - Contribution of stabilizing agents present in intravenous immunoglobulin 
      preparations to modulation of mononuclear cell proliferation in vitro.
PG  - 585-91
AB  - Intravenous immunoglobulin (IVIG) preparations have been shown to suppress 
      lymphocyte proliferation in vitro. This study aimed to investigate the effects of 
      an IVIG produced by fractionation/DEAE-Sephadex adsorption on lymphocyte 
      proliferation in vitro, with particular reference to contributions of the 
      stabilizing agents present in the IVIG to the modulation of mononuclear cell 
      proliferation. It was found that glycine significantly inhibited stimulation by 
      the mitogenic lectin phytohaemagglutinin (PHA; 58% inhibition, P < 0.01). Glucose 
      and human albumin also reduced the response to PHA but to a lesser extent (20% 
      and 30%, respectively). In further experiments the effects of sucrose and 
      maltose, two disaccharides used as stabilizing agents in IVIG preparations, were 
      studied. Three doses were used (2.5 mM, 25 mM and 250 mM), representing levels 
      likely to be found in vivo after infusion of IVIG at immunotherapeutic doses, on 
      four different proliferative stimuli. Maltose was found to inhibit proliferation 
      to PHA, anti-CD3 and PMA in a dose responsive manner. Sucrose also inhibited 
      proliferation to these stimuli, but a dose response was not observed. For both 
      sugars, only the highest dose (250 mM) inhibited the proliferative response of 
      mononuclear cells to PMA and a calcium ionophore (ionomycin). The repurified IgG 
      component of the IVIG preparation did not inhibit PBMC responses to PHA in this 
      system. Kinetic analyses, in which the sugars were added 24 h after proliferative 
      stimuli, indicated that both sugars still inhibited responses to PHA, and, to a 
      lesser extent, PMA, but only maltose inhibited the anti-CD3 response. These 
      findings show that stabilizing agents currently found in commercial IVIG 
      preparations make a significant contribution to modulating mononuclear cell 
      proliferation and need to be considered when assessing the immunomodulatory role 
      of IVIG in vitro.
FAU - Alder, L B
AU  - Alder LB
AD  - Department of Immunology, Medical School, University of Newcastle upon Tyne, UK.
FAU - Morgan, L A
AU  - Morgan LA
FAU - Spickett, G P
AU  - Spickett GP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (Excipients)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Mitogens)
RN  - 0 (Phytohemagglutinins)
RN  - 57-50-1 (Sucrose)
RN  - 69-79-4 (Maltose)
SB  - IM
MH  - Cell Division
MH  - Excipients/*pharmacology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - Lymphocytes/cytology/*drug effects
MH  - Maltose/pharmacology
MH  - Mitogens/pharmacology
MH  - Phytohemagglutinins/pharmacology
MH  - Sucrose/pharmacology
MH  - Time Factors
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1046/j.1365-3083.1996.d01-350.x [doi]
PST - ppublish
SO  - Scand J Immunol. 1996 Dec;44(6):585-91. doi: 10.1046/j.1365-3083.1996.d01-350.x.